Search results for " Positron emission tomography"

showing 10 items of 22 documents

Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics

2021

Graphical abstract

ATP Adenosine-triphosphateNBD nucleotide binding domainGSH reduced glutathionePolypharmacologyAlzheimer’s disease (AD)ATP-binding cassette transporterHTS high-throughput screeningBiochemistryABCA7Structural BiologyPLIF protein ligand interactionMSD membrane spanning domainPDB protein data bankTM transmembrane helixABC ATP-binding cassetteMultitarget modulation (PANABC)RMSD root mean square distanceABC transporter (ABCA1 ABCA4 ABCA7)Computer Science ApplicationsMOE Molecular Operating EnvironmentPharmacophoreSNP single-nucleotide polymorphismBiotechnologyResearch ArticleBBB blood-brain barrierBiophysicsDrug designComputational biologyBiologyAD Alzheimer’s diseasePET positron emission tomographyIC intracellular helixAPP amyloid precursor proteincryo-EM cryogenic-electron microscopyGeneticsHomology modelingBinding siteRational drug design and developmentComputingMethodologies_COMPUTERGRAPHICSNBD-cholesterol 7-nitro-2-13-benzoxadiazol-4-yl-cholesterolTransporterPSO particle swarm optimizationPET tracer (PETABC)ECD extracellular domainR-domain/region regulatory domain/regionABCA1biology.proteinEH extracellular helixTP248.13-248.65BODIPY-cholesterol 44-difluoro-4-bora-3a4a-diaza-s-indacene-cholesterolComputational and Structural Biotechnology Journal
researchProduct

Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

2016

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…

AdultMaleLung NeoplasmsTime FactorsAntineoplastic AgentsKaplan-Meier EstimateAdult; Aged; Antineoplastic Agents; Carcinoma Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Time Factors; Treatment OutcomeResponse evaluation criteria in solid tumorDisease-Free SurvivalErlotinib Hydrochloridenon–small cell lung cancerPositron Emission Tomography Computed TomographyHumansProspective StudiesNon-Small-Cell LungAgedCarcinomaMiddle AgedCarcinoma non-small-cell lungEORTCTreatment OutcomeRECISTResponse evaluation criteria in solid tumorsFemalePositron-emission tomographyPERCISTDiagnosi18F-FDG PET
researchProduct

Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imag…

2002

Detection of disease activity in Crohn's disease (CD) is of crucial importance for diagnosis and management of the disease. Noninvasive methods for monitoring are desirable and comprise hydromagnetic resonance imaging (hydro-MRI) and leukocyte scintigraphy. In addition, a recent case report indicated the potential of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to assess CD activity. However, comparative prospective studies are lacking.Between February, 1999 and August, 2000, 59 patients with CD were enrolled in a prospective study to assess disease activity by FDG-PET, hydro-MRI, and immunoscintigraphy with anti-nonspecific cross-reacting antigen 95 antigranulocyte antibod…

AdultMalePathologymedicine.medical_specialtyGranulocyteScintigraphySensitivity and SpecificityDisease activityFluorodeoxyglucose positron emission tomographyCrohn DiseaseAntigens NeoplasmFluorodeoxyglucose F18medicineHumansProspective StudiesTomography Emission-Computed Single-PhotonCrohn's diseaseMembrane GlycoproteinsHepatologymedicine.diagnostic_testbiologybusiness.industryGastroenterologyAntibodies MonoclonalColonoscopymedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structurePositron emission tomographybiology.proteinFemaleTomographyAntibodyRadiopharmaceuticalsbusinessNuclear medicineCell Adhesion MoleculesGranulocytesThe American journal of gastroenterology
researchProduct

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct

10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.

2020

Purpose The primary aim of this multicenter retrospective analysis is to examine the role of(18)F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive(18)F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. Materials and Methods This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent(18)F-choline PET/CT scans before receiving definitive treatments for a primary PCa…

Biochemical recurrenceMalemedicine.medical_specialtyProstate biopsyrecurrencePET/CTcholine; PET/CT; prostate cancer; recurrence; staging030218 nuclear medicine & medical imagingCholine03 medical and health sciencesProstate cancer0302 clinical medicineSettore MED/36ProstatePositron Emission Tomography Computed Tomography80 and overMedicineHumansRadiology Nuclear Medicine and imagingTomographyCancer stagingAgedAged 80 and overPET-CTmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsRetrospective cohort studyGeneral MedicinestagingMiddle Agedmedicine.diseaseprostate cancerX-Ray ComputedProstate-specific antigenmedicine.anatomical_structurePET030220 oncology & carcinogenesisRadiologyNeoplasm GradingRadiopharmaceuticalsbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedCT; choline; prostate cancer; recurrence; staging; Aged; Aged 80 and over; Choline; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography X-Ray ComputedCTClinical nuclear medicine
researchProduct

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

2019

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supp…

Cancer Researchmedicine.medical_specialtypositron emission tomographymedicine.medical_treatmentReviewlcsh:RC254-282meningioma030218 nuclear medicine & medical imagingMeningioma03 medical and health sciences0302 clinical medicineNeuroimagingFunctional neuroimagingmedicineotorhinolaryngologic diseasesMedical diagnosisRadiation treatment planningGrading (tumors)neoplasmsMeningioma; Neuroimaging; Positron emission tomography; Radionuclide therapy; Somatostatin receptorneuroimagingbusiness.industryradionuclide therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasesomatostatin receptorOncologymeningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy030220 oncology & carcinogenesisRadionuclide therapyRadiologybusinessWatchful waitingCancers
researchProduct

PET/CT and contrast enhanced CT in single vs. two separate sessions: a cost analysis study

2012

AIM: Aim of the study was to quantify the economic impact of PET/CT and contrast enhanced (c.e.) CT performed in a single session examination vs. stand-alone modalities in oncological patients. METHODS: One-hundred-forty-five cancer patients referred to both PET/CT and c.e. CT, to either stage (N.=46) or re-stage (N.=99) the disease, were included. Seventy-two/145 performed both studies in a single session (innovative method) and 73/145 in two different sessions (traditional method). The cost-minimization analysis was performed by evaluating: 1) institutional costs, data obtained by hospital accountability (staff, medical materials, equipment maintenance and depreciation, departments utilit…

Costs and cost analysis Positron emission tomography and computed tomography oncologySettore MED/36 - Diagnostica Per Immagini E RadioterapiaSettore SECS-P/06 - Economia Applicata
researchProduct

Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomic…

2022

Featured Application Based on results defined in this study, new investigations might propose morpho-functional-based radiomics algorithms for risk stratification with possible impact on treatment management in colorectal cancer. The aim of this study was to investigate the application of [F-18]FDG PET/CT images-based textural features analysis to propose radiomics models able to early predict disease progression (PD) and survival outcome in metastatic colorectal cancer (MCC) patients after first adjuvant therapy. For this purpose, 52 MCC patients who underwent [F-18]FDGPET/CT during the disease restaging process after the first adjuvant therapy were analyzed. Follow-up data were recorded f…

Fluid Flow and Transfer ProcessescolonradiomicsProcess Chemistry and TechnologyGeneral Engineeringpositron emission tomography-computed tomographycancercolon; cancer; radiomics; artificial intelligence; positron emission tomography-computed tomography; nuclear medicineGeneral Materials Sciencenuclear medicineartificial intelligenceInstrumentationComputer Science Applications
researchProduct

124I Radiolabeling of a AuIII‐NHC Complex for In Vivo Biodistribution Studies†

2020

Abstract AuIII complexes with N‐heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new AuIII‐NHC complexes by direct oxidation with radioactive [124I]I2 as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of AuIII‐to‐AuI reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the AuIII‐NHC prodrug is not immediately reduced after administration but able to reach the major…

Imaging Agents | Hot Paperpositron emission tomography010405 organic chemistryChemistryGeneral ChemistryProdrug010402 general chemistryanticancer01 natural sciencesCombinatorial chemistryCatalysisIn vitro3. Good health0104 chemical sciencesIn vivoIn vivo biodistributionSettore CHIM/03 - Chimica Generale E InorganicametallodrugsN-heterocyclic carbenesanticancer; metallodrugs; N-heterocyclic carbenes; positron emission tomography; radiochemistryradiochemistryResearch ArticlesResearch ArticleAngewandte Chemie (International Ed. in English)
researchProduct

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway

2017

AbstractSkeletal erosion has been found to represent an independent prognostic indicator in patients with advanced stages of chronic lymphocytic leukaemia (CLL). Whether this phenomenon also occurs in early CLL phases and its underlying mechanisms have yet to be fully elucidated. In this study, we prospectively enrolled 36 consecutive treatment-naïve patients to analyse skeletal structure and bone marrow distribution using a computational approach to PET/CT images. This evaluation was combined with the analysis of RANK/RANKL loop activation in the leukemic clone, given recent reports on its role in CLL progression. Bone erosion was particularly evident in long bone shafts, progressively inc…

Male0301 basic medicineChronic lymphocytic leukaemiaClone (cell biology)Osteoclastslcsh:MedicineMice0302 clinical medicineMice Inbred NODBone MarrowPositron Emission Tomography Computed Tomographyhemic and lymphatic diseases80 and overProspective StudiesChroniclcsh:ScienceAged 80 and overSettore ING-IND/24 - Principi Di Ingegneria ChimicaLeukemiaMultidisciplinaryBone Density Conservation AgentsReceptor Activator of Nuclear Factor-kappa BbiologyMiddle AgedLymphocyticLeukemiamedicine.anatomical_structureDenosumabRANKL030220 oncology & carcinogenesisFemaleDenosumabmedicine.drugAdultStromal cellArticle03 medical and health sciencesOsteoclastmedicineAnimalsHumansAgedRANK/RANKL Pathwaybusiness.industryRANK Ligandlcsh:RB-CellDiagnostic markersRANK LigandAdult; Aged; Aged 80 and over; Animals; Bone Density Conservation Agents; Bone Marrow; Denosumab; Female; Glucose; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Mice Inbred NOD; Middle Aged; Osteoclasts; Positron Emission Tomography Computed Tomography; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Xenograft Model Antitumor Assaysmedicine.diseaseLeukemia Lymphocytic Chronic B-CellXenograft Model Antitumor AssaysGlucose030104 developmental biologyChronic Lymphocytic Leukaemiabiology.proteinCancer researchInbred NODlcsh:QBone marrowbusiness
researchProduct